Research programme: mRNA therapeutics - Nutcracker Therapeutics
Latest Information Update: 05 May 2023
At a glance
- Originator Nutcracker Therapeutics
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Protein synthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer